SUMMARY Forty patients with endoscopically proven persistent duodenal ulcer who had been treated for six weeks with cimetidine (1 g/day) were randomly allocated to receive a further six weeks' treatment with cimetidine (1 g/day) or ranitidine (300 mg/day). Ulcers healed in 12 of 19 patients given cimetidine (63%) and in 13 of 21 given ranitidine (62%); two patients on cimetidine and two on ranitidine dropped out. In the unhealed ulcer group the ulcer size was reduced in most patients. There was no change in basal acid output, peak acid output, plasma gastrin and pepsinogen I levels after either treatment. Clinical data, gastric function tests, and endoscopic features did not predict ulcer healing. Both treatments were effective in the relief of pain: 72% of patients with unhealed ulcers were asymptomatic at the end of the trial.
The histamine H2-receptor antagonist cimetidine usually heals 70-80% of chronic duodenal ulcers in four to six weeks' treatment.1 Some of the unhealed peptic ulcers can be successfully treated by prolonging the cimetidine administration for up to three months.2 In recent uncontrolled trials, ranitidine has been reported to give better results in the management of these ulcers unhealed by cimetidine. _36
In order to evaluate the effect of ranitidine in the treatment of such ulcers, we performed a randomised clinical trial comparing ranitidine with cimetidine in patients with chronic duodenal ulcers unhealed by six weeks' cimetidine treatment (1 g/day The two treatment groups were comparable at trial entry for age, sex, family history of peptic ulcer, duration of dyspeptic symptoms, night and day pain, subjective wellbeing, and daily consumption of cigarettes, coffee and alcohol, as well as for ulcer size and morphology (Table 1) ; they were also comparable for BAO, PAO, plasma gastrin and pepsinogen I (Table 2) .
Ulcers healed in 12 patients on cimetidine (63%) and in 13 on ranitidine (62%) ( Table 3 ). In the unhealed groups total ulcer area decreased after cimetidine and ranitidine treatment respectively from 241 and 685 to 79 and 265 mm2 (Fig. 1) .
Both treatments produced a similar improvement in night and day pain and subjective wellbeing. Antacids were taken only by a small percentage of patients during the first two weeks; consumption was low and similar in the two treatment groups.
After cimetidine or ranitidine treatment, no significant differences were found in either group for BAO, PAO, plasma gastrin or pepsinogen I, compared with the pretreatment values or between the two treatment groups at the end of the trial (Table 2) .
Subdividing the patients into two groups according to whether their ulcers had healed or not at trial completion, these two groups were comparable for age, sex, coffee and alcohol consumption, family history of peptic ulcer, day and night pain, subjective wellbeing, and ulcer size. A longer history of dyspeptic symptoms was observed in the healed than in the unhealed ulcer patients, although the difference did not reach significance (Table 4) ; a positive correlation (p<0-01) was found (Table 6 ). At the first endoscopy, round ulcers were found in 20, oval in four and linear in one of the healed ulcer patients, and respectively in eight, two and one of the unhealed ulcer patients. In the 11 unhealed ulcer patients the total ulcerated area reduced from 926 to 344 mm2; in one case only was an increase in the ulcerated area found (9-25 mm2) (Fig. 1) .
The percentage of patients with day and/or night pain and the average score of subjective wellbeing were similar in the healed and unhealed ulcer groups. The percentage of asymptomatic patients increased markedly in the first two weeks, and at the end of the trial two patients (8%) with healed ulcers and three patients (28%) with unhealed ulcers had symptoms (Fig. 2) .
No significant modifications of routine haematologic and biochemical tests were found after either treatment; no side effects due to the treatments were reported by the patients.
Discussion
It should be noted that in this trial the total ulcer population from which our patients were drawn could not be determined, owing to the fact that the Ranitidine (300 mg/day) and cimetidine (1 g/day)
were equally effective in the healing of chronic duodenal ulcers unhealed by previous treatment with cimetidine (1 g/day) for six weeks. These results suggest that the effect of the two drugs in the treatment of 'cimetidine-resistant' ulcers do not greatly differ; however, because of the limited number of the patients studied, the confidence limits of the healing rates were wide and to exclude smaller differences larger series are needed. Patient compliance was good on both treatment schedules. These results do not agree with previous data suggesting that the more potent H2 antagonist rantidine with its simpler schedule could be more effective in the treatment of 'cimetidine-resistant' duodenal ulcers.36
In our study, prolonged treatment, regardless of 
